Skip to main content

Table 2 List of clinical trials included in the ORR analysis

From: Agnostic evaluation of ipilimumab and nivolumab association: a metanalysis

Study No. patients ORR
CA209-067 n + i = 314
n = 316
n + i = 58.3%
n = 44.6%
CA209-227 n + i = 396
n = 396
n + i = 35.9%
n = 27.5%
IFCT-1501 MAPS2 n + i = 54
n = 54
n + i = 27.8%
n = 18.5%
Alliance A091401 n + i = 38
n = 38
n + i = 15.8%
n = 5.3%
CA209-032 (GastricCancer) n + i = 49*
n + i = 52**
n = 59
n + i = 24.5%
n + i = 7.7%
n = 11.9%
CA209-032 (BladderCancer) n + i = 196
n = 78
n + i = 34%
n = 24%
CA209-032 (SCLC) n + i = 147
n = 95
n + i = 21%
n = 12%
  1. *Nivo 3 mg + IPI 1 mg. **Nivo 1 mg + IPI 3 mg